Download Free Developing A National Sentinel Surveillance System For Antimicrobial Resistant Neisseria Gonorrhoeae In Ireland Book in PDF and EPUB Free Download. You can read online Developing A National Sentinel Surveillance System For Antimicrobial Resistant Neisseria Gonorrhoeae In Ireland and write the review.

Background:Ireland has participated in the Euro-GASP (European Gonococcal Antimicrobial Surveillance Programme) sentinel surveillance programme since 2010. The central pathology laboratory in St. Jamesu2019s Hospital is the Irish sentinel laboratory for Euro GASP and, in 2017, was designated the National Interim Gonococcal Reference Laboratory. Previously, Irish samples for Euro-GASP were selected consecutively from specimens collected in Dublin, but in 2017 isolates were submitted from laboratories nationwide.Methods:Euro-GASP isolates were tested for susceptibility to clinically relevant antimicrobials using Etests and for penicillinase production using Nitrocefin. Etest results were interpreted using EUCAST breakpoints. Epidemiological data on mode of transmission, HIV status, other STIs and country of birth were collected. Data were analysed using Stata and Excel.Results:775 Irish isolates were reported to Euro-GASP between 2010 and 2017 (capturing 7% of national notifications reported by routine surveillance during that time), 92% males and 8% females. Trends varied due to sampling bias in early years and increased representativeness in 2017. Overall mode of transmission was reported as MSM in 78% and heterosexual in 22%. The age range was 15 u2013 65 years; median 28 years among males and 23 years among females. 10% of patients were HIV positive (all MSM), 21% had a previous gonorrhoea infection and 14% had concurrent chlamydia infections. 45% of patients were born in Ireland and 13% in Latin America. While 99% of isolates remained susceptible to cefixime and ceftriaxone, 36% were resistant to ciprofloxacin, 13% resistant to azithromycin and 9% produced penicillinase. Conclusions:In Ireland surveillance of gonorrhoea antimicrobial resistance has focussed on isolates from one region. The designation of the Interim Gonococcal Reference Laboratory has permitted movement towards a more nationally representative sentinel surveillance system. Continuation of this strengthened surveillance of gonorrhoea antimicrobial resistance increases the validity of Irish data in the context of European and global data.
The Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) aims to strengthen sentinel surveillance for gonococcal antimicrobial resistance (AMR) in selected countries. EGASP monitors trends in antimicrobial susceptibility in Neisseria gonorrhoeae by using standardized sampling and laboratory protocols linked to epidemiological data in participating countries. EGASP contributes to the WHO global action plan on antimicrobial resistance, 2015. EGASP is a special project under the Global Antimicrobial Resistance Surveillance System (GLASS). EGASP is a collaborative effort between the WHO, the United States Centers for Disease Control and Prevention (CDC) and WHO collaborating centres on STIs. The protocol document describes the objectives and the methods of EGASP surveillance and guidance on how to implement and monitor EGASP. This publication targets the national sexually transmitted infection and antimicrobial resistance programmes and other institutions to strengthen gonorrhoea AMR surveillance system. This surveillance protocol allows collaborators to improve the quality, comparability and timeliness of gonococcal antimicrobial resistance data across multiple countries. It also aims to enhance the capacity for early detection of emergence of resistance in N. gonorrhoeae strains to recommended treatment.
Summary report published as technical document with reference number: WHO/HSE/PED/AIP/2014.2.
This fully updated edition of Infectious Disease Surveillance is for frontline public health practitioners, epidemiologists, and clinical microbiologists who are engaged in communicable disease control. It is also a foundational text for trainees in public health, applied epidemiology, postgraduate medicine and nursing programs. The second edition portrays both the conceptual framework and practical aspects of infectious disease surveillance. It is a comprehensive resource designed to improve the tracking of infectious diseases and to serve as a starting point in the development of new surveillance systems. Infectious Disease Surveillance includes over 45 chapters from over 100 contributors, and topics organized into six sections based on major themes. Section One highlights the critical role surveillance plays in public health and it provides an overview of the current International Health Regulations (2005) in addition to successes and challenges in infectious disease eradication. Section Two describes surveillance systems based on logical program areas such as foodborne illnesses, vector-borne diseases, sexually transmitted diseases, viral hepatitis healthcare and transplantation associated infections. Attention is devoted to programs for monitoring unexplained deaths, agents of bioterrorism, mass gatherings, and disease associated with international travel. Sections Three and Four explore the uses of the Internet and wireless technologies to advance infectious disease surveillance in various settings with emphasis on best practices based on deployed systems. They also address molecular laboratory methods, and statistical and geospatial analysis, and evaluation of systems for early epidemic detection. Sections Five and Six discuss legal and ethical considerations, communication strategies and applied epidemiology-training programs. The rest of the chapters offer public-private partnerships, as well lessons from the 2009-2010 H1N1 influenza pandemic and future directions for infectious disease surveillance.
Antibiotic resistance is neither a surprising nor a new phenomenon. It is an increasingly worrisome situation, however, because resistance is growing and accelerating while the world's tools for combating it decrease in power and number. In addition, the cost of the problemâ€"especially of multidrug resistanceâ€"in terms of money, mortality, and disability are also rising. This book summarizes a workshop on antimicrobial resistance held by the Forum on Emerging Infections. The goal of the Forum on Emerging Infections is to provide an opportunity for representatives of academia, industry, government, and professional and interest groups to examine and discuss scientific and policy dilemmas of common interest that are specifically related to research on and the prevention, detection, and management of emerging infections. Organized as a topic-by-topic synthesis of presentations and exchanges during the workshop, the book highlights lessons learned, delineates a range of pivotal issues and the problems they raise, and proposes some simplified ideas about possible responses.
After thirty five years, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition is still the reference of choice for comprehensive, global guidance on diagnosing and treating the most challenging infectious diseases. Drs. John E. Bennett and Raphael Dolin along with new editorial team member Dr. Martin Blaser have meticulously updated this latest edition to save you time and to ensure you have the latest clinical and scientific knowledge at your fingertips. With new chapters, expanded and updated coverage, increased worldwide perspectives, and many new contributors, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition helps you identify and treat whatever infectious disease you see. Get the answers to questions you have with more in-depth coverage of epidemiology, etiology, pathology, microbiology, immunology, and treatment of infectious agents than you'll find in any other infectious disease resource. Find the latest diagnoses and treatments for currently recognized and newly emerging infectious diseases, such as those caused by avian and swine influenza viruses. Put the latest knowledge to work in your practice with new or completely revised chapters on influenza (new pandemic strains); new Middle East respiratory syndrome (MERS) virus; probiotics; antibiotics for resistant bacteria; antifungal drugs; new antivirals for hepatitis B and C; Clostridium difficile treatment; sepsis; advances in HIV prevention and treatment; viral gastroenteritis; Lyme disease; Helicobacter pylori; malaria; infections in immunocompromised hosts; immunization (new vaccines and new recommendations); and microbiome. Benefit from fresh perspectives and global insights from an expanded team of international contributors. Find and grasp the information you need easily and rapidly with newly added chapter summaries. These bulleted templates include diagnosis, therapy, and prevention and are designed as a quick summary of the chapter and to enhance relevancy in search and retrieval on Expert Consult. Stay current on Expert Consult with a thorough and regularly scheduled update program that ensures access to new developments in the field, advances in therapy, and timely information. Access the information you need easily and rapidly with new succinct chapter summaries that include diagnosis, therapy, and prevention. Experience clinical scenarios with vivid clarity through a richly illustrated, full-color format that includes 1500 photographs for enhanced visual guidance.
After thirty five years, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition is still the reference of choice for comprehensive, global guidance on diagnosing and treating the most challenging infectious diseases. Drs. John E. Bennett and Raphael Dolin along with new editorial team member Dr. Martin Blaser have meticulously updated this latest edition to save you time and to ensure you have the latest clinical and scientific knowledge at your fingertips. With new chapters, expanded and updated coverage, increased worldwide perspectives, and many new contributors, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition helps you identify and treat whatever infectious disease you see. Get the answers to any questions you have with more in-depth coverage of epidemiology, etiology, pathology, microbiology, immunology, and treatment of infectious agents than you’ll find in any other ID resource. Apply the latest knowledge with updated diagnoses and treatments for currently recognized and newly emerging infectious diseases, such as those caused by avian and swine influenza viruses. Put the latest knowledge to work in your practice with new or completely revised chapters on Influenza (new pandemic strains); New Middle East Respiratory Syndrome (MERS) Virus; Probiotics; Antibiotics for resistant bacteria; Antifungal drugs; New Antivirals for hepatitis B and C; Clostridium difficile treatment; Sepsis; Advances in HIV prevention and treatment; Viral gastroenteritis; Lyme Disease; Helicobacter pylori; Malaria; Infections in immunocompromised hosts; Immunization (new vaccines and new recommendations); and Microbiome. Benefit from fresh perspectives and expanded global insights from an expanded team of American and International contributors. Martin Blaser, MD, a leading expert and Muriel G. and George W. Singer Professional of Translational Medicine at New York University School of Medicine, joins veteran PPID editors John E. Bennett, MD, and Raphael Dolin, MD to continue a legacy of excellence. Find and grasp the information you need easily and rapidly with newly added chapter summaries.
This comprehensive, well-illustrated, and easily accessible book documents the latest research outcomes concerning sexually transmitted infections (STIs) and describes important advances in their prevention, diagnosis and treatment. The changes in the epidemiology and clinical aspects of STIs that have occurred over the past decade are fully explored, with special attention to core groups and patients with immunological disorders. The emerging challenges associated with particular sexually transmitted pathogens, including C. trachomatis, N. gonorrhoeae, HPV, and HIV, are identified and discussed. Readers will find detailed information on modern preventive strategies, new laboratory and diagnostic techniques, and a range of innovative treatments, including vaccines, continuous antiretroviral therapy, and new drugs against hepatitis viruses. Attention is also drawn to new directions in biomedical research that promise clinical benefits for the patients and communities. The combination of a detailed clinical and research approach, with emphasis on new knowledge and innovative aspects, ensures that the book will be of value to a wide readership comprising both clinicians and researchers.
When Antibiotics Fail examines the current impacts of AMR on our healthcare system, projects the future impact on Canada’s GDP, and looks at how widespread resistance will influence the day-to-day lives of Canadians. The report examines these issues through a One Health lens, recognizing the interconnected nature of AMR, from healthcare settings to the environment to the agriculture sector. It is the most comprehensive report to date on the economic impact of AMR in Canada.
"This text presents an organized approach to planning, developing, and implementing public health surveillance systems. It has a broad scope, discussing legal and ethical issues as well as technical problems"--Jacket cover.